Uncovering the genomic heterogeneity of multifocal breast cancer

Christine Desmedt, Debora Fumagalli, Elisabetta Pietri, Gabriele Zoppoli, David Brown, Serena Nik-Zainal, Gunes Gundem, Françoise Rothé, Samira Majjaj, Anna Garuti, Enrico Carminati, Sherene Loi, Thomas Van Brussel, Bram Boeckx, Marion Maetens, Laura Mudie, Delphine Vincent, Naima Kheddoumi, Luigi Serra, Ilaria Massa & 9 others Alberto Ballestrero, Dino Amadori, Roberto Salgado, Alexandre De Wind, Diether Lambrechts, Martine Piccart, Denis Larsimont, Peter J. Campbell, Christos Sotiriou

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Multifocal breast cancer (MFBC), defined as multiple synchronous unilateral lesions of invasive breast cancer, is relatively frequent and has been associated with more aggressive features than unifocal cancer. Here, we aimed to investigate the genomic heterogeneity between MFBC lesions sharing similar histopathological parameters. Characterization of different lesions from 36 patients with ductal MFBC involved the identification of non-silent coding mutations in 360 protein-coding genes (171 tumour and 36 matched normal samples). We selected only patients with lesions presenting the same grade, ER, and HER2 status. Mutations were classified as 'oncogenic' in the case of recurrent substitutions reported in COSMIC or truncating mutations affecting tumour suppressor genes. All mutations identified in a given patient were further interrogated in all samples from that patient through deep resequencing using an orthogonal platform. Whole-genome rearrangement screen was further conducted in 8/36 patients. Twenty-four patients (67%) had substitutions/indels shared by all their lesions, of which 11 carried the same mutations in all lesions, and 13 had lesions with both common and private mutations. Three-quarters of those 24 patients shared oncogenic variants. The remaining 12 patients (33%) did not share any substitution/indels, with inter-lesion heterogeneity observed for oncogenic mutation(s) in genes such as PIK3CA, TP53, GATA3, and PTEN. Genomically heterogeneous lesions tended to be further apart in the mammary gland than homogeneous lesions. Genome-wide analyses of a limited number of patients identified a common somatic background in all studied MFBCs, including those with no mutation in common between the lesions. To conclude, as the number of molecular targeted therapies increases and trials driven by genomic screening are ongoing, our findings highlight the presence of genomic inter-lesion heterogeneity in one-third, despite similar pathological features. This implies that deeper molecular characterization of all MFBC lesions is warranted for the adequate management of those cancers.

Original languageEnglish
Pages (from-to)457-466
Number of pages10
JournalJournal of Pathology
Volume236
Issue number4
DOIs
Publication statusPublished - Aug 1 2015

Fingerprint

Breast Neoplasms
Mutation
Genome
Molecular Targeted Therapy
Neoplasms
Human Mammary Glands
Tumor Suppressor Genes
Genes
Proteins

Keywords

  • breast cancer
  • genomic heterogeneity
  • multicentric
  • multifocal
  • oncogenic mutations
  • targeted sequencing

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

Desmedt, C., Fumagalli, D., Pietri, E., Zoppoli, G., Brown, D., Nik-Zainal, S., ... Sotiriou, C. (2015). Uncovering the genomic heterogeneity of multifocal breast cancer. Journal of Pathology, 236(4), 457-466. https://doi.org/10.1002/path.4540

Uncovering the genomic heterogeneity of multifocal breast cancer. / Desmedt, Christine; Fumagalli, Debora; Pietri, Elisabetta; Zoppoli, Gabriele; Brown, David; Nik-Zainal, Serena; Gundem, Gunes; Rothé, Françoise; Majjaj, Samira; Garuti, Anna; Carminati, Enrico; Loi, Sherene; Van Brussel, Thomas; Boeckx, Bram; Maetens, Marion; Mudie, Laura; Vincent, Delphine; Kheddoumi, Naima; Serra, Luigi; Massa, Ilaria; Ballestrero, Alberto; Amadori, Dino; Salgado, Roberto; De Wind, Alexandre; Lambrechts, Diether; Piccart, Martine; Larsimont, Denis; Campbell, Peter J.; Sotiriou, Christos.

In: Journal of Pathology, Vol. 236, No. 4, 01.08.2015, p. 457-466.

Research output: Contribution to journalArticle

Desmedt, C, Fumagalli, D, Pietri, E, Zoppoli, G, Brown, D, Nik-Zainal, S, Gundem, G, Rothé, F, Majjaj, S, Garuti, A, Carminati, E, Loi, S, Van Brussel, T, Boeckx, B, Maetens, M, Mudie, L, Vincent, D, Kheddoumi, N, Serra, L, Massa, I, Ballestrero, A, Amadori, D, Salgado, R, De Wind, A, Lambrechts, D, Piccart, M, Larsimont, D, Campbell, PJ & Sotiriou, C 2015, 'Uncovering the genomic heterogeneity of multifocal breast cancer', Journal of Pathology, vol. 236, no. 4, pp. 457-466. https://doi.org/10.1002/path.4540
Desmedt C, Fumagalli D, Pietri E, Zoppoli G, Brown D, Nik-Zainal S et al. Uncovering the genomic heterogeneity of multifocal breast cancer. Journal of Pathology. 2015 Aug 1;236(4):457-466. https://doi.org/10.1002/path.4540
Desmedt, Christine ; Fumagalli, Debora ; Pietri, Elisabetta ; Zoppoli, Gabriele ; Brown, David ; Nik-Zainal, Serena ; Gundem, Gunes ; Rothé, Françoise ; Majjaj, Samira ; Garuti, Anna ; Carminati, Enrico ; Loi, Sherene ; Van Brussel, Thomas ; Boeckx, Bram ; Maetens, Marion ; Mudie, Laura ; Vincent, Delphine ; Kheddoumi, Naima ; Serra, Luigi ; Massa, Ilaria ; Ballestrero, Alberto ; Amadori, Dino ; Salgado, Roberto ; De Wind, Alexandre ; Lambrechts, Diether ; Piccart, Martine ; Larsimont, Denis ; Campbell, Peter J. ; Sotiriou, Christos. / Uncovering the genomic heterogeneity of multifocal breast cancer. In: Journal of Pathology. 2015 ; Vol. 236, No. 4. pp. 457-466.
@article{8d252ba7703146108e727da83457cd7b,
title = "Uncovering the genomic heterogeneity of multifocal breast cancer",
abstract = "Multifocal breast cancer (MFBC), defined as multiple synchronous unilateral lesions of invasive breast cancer, is relatively frequent and has been associated with more aggressive features than unifocal cancer. Here, we aimed to investigate the genomic heterogeneity between MFBC lesions sharing similar histopathological parameters. Characterization of different lesions from 36 patients with ductal MFBC involved the identification of non-silent coding mutations in 360 protein-coding genes (171 tumour and 36 matched normal samples). We selected only patients with lesions presenting the same grade, ER, and HER2 status. Mutations were classified as 'oncogenic' in the case of recurrent substitutions reported in COSMIC or truncating mutations affecting tumour suppressor genes. All mutations identified in a given patient were further interrogated in all samples from that patient through deep resequencing using an orthogonal platform. Whole-genome rearrangement screen was further conducted in 8/36 patients. Twenty-four patients (67{\%}) had substitutions/indels shared by all their lesions, of which 11 carried the same mutations in all lesions, and 13 had lesions with both common and private mutations. Three-quarters of those 24 patients shared oncogenic variants. The remaining 12 patients (33{\%}) did not share any substitution/indels, with inter-lesion heterogeneity observed for oncogenic mutation(s) in genes such as PIK3CA, TP53, GATA3, and PTEN. Genomically heterogeneous lesions tended to be further apart in the mammary gland than homogeneous lesions. Genome-wide analyses of a limited number of patients identified a common somatic background in all studied MFBCs, including those with no mutation in common between the lesions. To conclude, as the number of molecular targeted therapies increases and trials driven by genomic screening are ongoing, our findings highlight the presence of genomic inter-lesion heterogeneity in one-third, despite similar pathological features. This implies that deeper molecular characterization of all MFBC lesions is warranted for the adequate management of those cancers.",
keywords = "breast cancer, genomic heterogeneity, multicentric, multifocal, oncogenic mutations, targeted sequencing",
author = "Christine Desmedt and Debora Fumagalli and Elisabetta Pietri and Gabriele Zoppoli and David Brown and Serena Nik-Zainal and Gunes Gundem and Fran{\cc}oise Roth{\'e} and Samira Majjaj and Anna Garuti and Enrico Carminati and Sherene Loi and {Van Brussel}, Thomas and Bram Boeckx and Marion Maetens and Laura Mudie and Delphine Vincent and Naima Kheddoumi and Luigi Serra and Ilaria Massa and Alberto Ballestrero and Dino Amadori and Roberto Salgado and {De Wind}, Alexandre and Diether Lambrechts and Martine Piccart and Denis Larsimont and Campbell, {Peter J.} and Christos Sotiriou",
year = "2015",
month = "8",
day = "1",
doi = "10.1002/path.4540",
language = "English",
volume = "236",
pages = "457--466",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Uncovering the genomic heterogeneity of multifocal breast cancer

AU - Desmedt, Christine

AU - Fumagalli, Debora

AU - Pietri, Elisabetta

AU - Zoppoli, Gabriele

AU - Brown, David

AU - Nik-Zainal, Serena

AU - Gundem, Gunes

AU - Rothé, Françoise

AU - Majjaj, Samira

AU - Garuti, Anna

AU - Carminati, Enrico

AU - Loi, Sherene

AU - Van Brussel, Thomas

AU - Boeckx, Bram

AU - Maetens, Marion

AU - Mudie, Laura

AU - Vincent, Delphine

AU - Kheddoumi, Naima

AU - Serra, Luigi

AU - Massa, Ilaria

AU - Ballestrero, Alberto

AU - Amadori, Dino

AU - Salgado, Roberto

AU - De Wind, Alexandre

AU - Lambrechts, Diether

AU - Piccart, Martine

AU - Larsimont, Denis

AU - Campbell, Peter J.

AU - Sotiriou, Christos

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Multifocal breast cancer (MFBC), defined as multiple synchronous unilateral lesions of invasive breast cancer, is relatively frequent and has been associated with more aggressive features than unifocal cancer. Here, we aimed to investigate the genomic heterogeneity between MFBC lesions sharing similar histopathological parameters. Characterization of different lesions from 36 patients with ductal MFBC involved the identification of non-silent coding mutations in 360 protein-coding genes (171 tumour and 36 matched normal samples). We selected only patients with lesions presenting the same grade, ER, and HER2 status. Mutations were classified as 'oncogenic' in the case of recurrent substitutions reported in COSMIC or truncating mutations affecting tumour suppressor genes. All mutations identified in a given patient were further interrogated in all samples from that patient through deep resequencing using an orthogonal platform. Whole-genome rearrangement screen was further conducted in 8/36 patients. Twenty-four patients (67%) had substitutions/indels shared by all their lesions, of which 11 carried the same mutations in all lesions, and 13 had lesions with both common and private mutations. Three-quarters of those 24 patients shared oncogenic variants. The remaining 12 patients (33%) did not share any substitution/indels, with inter-lesion heterogeneity observed for oncogenic mutation(s) in genes such as PIK3CA, TP53, GATA3, and PTEN. Genomically heterogeneous lesions tended to be further apart in the mammary gland than homogeneous lesions. Genome-wide analyses of a limited number of patients identified a common somatic background in all studied MFBCs, including those with no mutation in common between the lesions. To conclude, as the number of molecular targeted therapies increases and trials driven by genomic screening are ongoing, our findings highlight the presence of genomic inter-lesion heterogeneity in one-third, despite similar pathological features. This implies that deeper molecular characterization of all MFBC lesions is warranted for the adequate management of those cancers.

AB - Multifocal breast cancer (MFBC), defined as multiple synchronous unilateral lesions of invasive breast cancer, is relatively frequent and has been associated with more aggressive features than unifocal cancer. Here, we aimed to investigate the genomic heterogeneity between MFBC lesions sharing similar histopathological parameters. Characterization of different lesions from 36 patients with ductal MFBC involved the identification of non-silent coding mutations in 360 protein-coding genes (171 tumour and 36 matched normal samples). We selected only patients with lesions presenting the same grade, ER, and HER2 status. Mutations were classified as 'oncogenic' in the case of recurrent substitutions reported in COSMIC or truncating mutations affecting tumour suppressor genes. All mutations identified in a given patient were further interrogated in all samples from that patient through deep resequencing using an orthogonal platform. Whole-genome rearrangement screen was further conducted in 8/36 patients. Twenty-four patients (67%) had substitutions/indels shared by all their lesions, of which 11 carried the same mutations in all lesions, and 13 had lesions with both common and private mutations. Three-quarters of those 24 patients shared oncogenic variants. The remaining 12 patients (33%) did not share any substitution/indels, with inter-lesion heterogeneity observed for oncogenic mutation(s) in genes such as PIK3CA, TP53, GATA3, and PTEN. Genomically heterogeneous lesions tended to be further apart in the mammary gland than homogeneous lesions. Genome-wide analyses of a limited number of patients identified a common somatic background in all studied MFBCs, including those with no mutation in common between the lesions. To conclude, as the number of molecular targeted therapies increases and trials driven by genomic screening are ongoing, our findings highlight the presence of genomic inter-lesion heterogeneity in one-third, despite similar pathological features. This implies that deeper molecular characterization of all MFBC lesions is warranted for the adequate management of those cancers.

KW - breast cancer

KW - genomic heterogeneity

KW - multicentric

KW - multifocal

KW - oncogenic mutations

KW - targeted sequencing

UR - http://www.scopus.com/inward/record.url?scp=84937518723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937518723&partnerID=8YFLogxK

U2 - 10.1002/path.4540

DO - 10.1002/path.4540

M3 - Article

VL - 236

SP - 457

EP - 466

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 4

ER -